Abstract Number: 2596 • 2018 ACR/ARHP Annual Meeting
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) lead to a dramatic improvement in the management of psoriatic arthritis (PsA). Nevertheless, a significant proportion of patients…Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…Abstract Number: 2618 • 2018 ACR/ARHP Annual Meeting
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Background/Purpose: Ustekinumab and secukinumab are two new Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) in severe psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Data in…Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…Abstract Number: 1829 • 2018 ACR/ARHP Annual Meeting
Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
Background/Purpose: The microbiome serves a number of important functions, including modulation of the immune system and protection from pathogenic microorganisms1. Many autoimmune diseases have been…Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…Abstract Number: 1933 • 2018 ACR/ARHP Annual Meeting
Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Background/Purpose: Flares of immune-mediated inflammatory diseases, as Rheumatoid Arthritis (RA) occur unpredictably representing a major burden for patients and clinicians. We aimed to dissect the…Abstract Number: 2826 • 2018 ACR/ARHP Annual Meeting
Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease
Background/Purpose: Vedolizumab therapy for inflammatory bowel disease (IBD) has been associated with mild spondyloarthritis (SpA) related features including sacroiliitis and synovitis. Herein, we report a…Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…Abstract Number: 238 • 2017 ACR/ARHP Annual Meeting
Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors
Background/Purpose: Efficacy of cycling of TNF inhibitors, judged by composite measures, is inferior to non-TNF biologics in patients with RA inadequate response to previous TNF…Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…Abstract Number: 280 • 2017 ACR/ARHP Annual Meeting
Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Background/Purpose: immunosuppressive therapies and bDAMRDs expecially, increase the risk of infections. According to the EULAR guidelines, all patients affected by autoimmune/inflammatory diseases should receive vaccinations…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 14
- Next Page »